Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod vs Placebo and Avonex in RRMS (BRAVO)
NCT00605215Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2008
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of laquinimod in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Annualized Rate of Confirmed Relapses at 24 months. Started Apr 2008; status: completed.
02
Drugs
laquinimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00605215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00605215.